Research analysts covering Odyssey Health.
Recent press releases and 8-K filings for ODYY.
Odyssey Health Extends Maturity Dates on Multiple Promissory Notes
ODYY
Debt Issuance
- Odyssey Health, Inc. extended the maturity dates of several promissory notes and convertible promissory notes with various lenders, including directors, officers, and accredited investors, with effective dates around January 30, 2026.
- Four Convertible Promissory Notes, each for $25,000.00, with directors and officers, had their maturity dates extended to January 31, 2027.
- A Convertible Promissory Note for $1,050,000.00 with LGH Investments, LLC, had its maturity date extended to April 30, 2026.
- Promissory Notes with accredited investors Jonathan Lutz and Peter J. D'Arruda (for $300,000.00) also had their maturity dates extended to January 31, 2027.
4 days ago
Odyssey Health Secures Nine-Year Service Contract and $25 Million Financing Facility
ODYY
Debt Issuance
New Projects/Investments
Revenue Acceleration/Inflection
- Odyssey Health, Inc. secured a nine-year maintenance service contract for a commercial medical property, generating approximately $245,000 per year in recurring revenue, effective November 13, 2025.
- The company also secured a financing facility of up to $25 million, structured as a promissory note with a 10% original issue discount.
- An initial tranche of $500,000 from this facility, providing $437,500 in net proceeds to the company, will be used to advance the BreastCheck® sub-licensing program.
- In connection with the maintenance agreement, Odyssey issued a convertible promissory note for $2,262,000 to Mast Hill Fund, L.P., bearing 10% annual interest and due November 13, 2026.
Nov 19, 2025, 2:00 PM
Odyssey Health, Inc. Secures Exclusive Sub-License for BreastCheck® Device
ODYY
Product Launch
New Projects/Investments
- Odyssey Health, Inc. (ODYY), through its subsidiary Odyssey Medical Devices, Inc., has entered into a Master Technology Sub-License Agreement with NeuRX Health Inc. for exclusive, worldwide rights to the BreastCheck® device.
- The BreastCheck® is a non-invasive test for breast abnormalities that is FDA registered in the United States and registered with regulatory authorities in the European Union and the United Kingdom.
- This agreement allows Odyssey Health to enter the $26 billion breast cancer marketplace, with the company expecting to begin commercialization and generate initial revenue soon.
- Consideration for the sub-license includes cash payments based on a percentage of net cash proceeds from equity line of credit draws, and royalty payments for each BreastCheck® unit sold.
Oct 17, 2025, 9:10 PM
Odyssey Health Secures Worldwide Rights for BreastCheck®
ODYY
Product Launch
New Projects/Investments
- Odyssey Health, Inc. (OTCQB: ODYY) has signed a sub-licensing agreement for exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities.
- BreastCheck® is a home-use test that provides immediate results in 15 minutes and is FDA registered in the United States, as well as registered with regulatory authorities in the EU and UK.
- CEO Michael Redmond expects commercialization and initial revenue from BreastCheck® in the near future, marking the company's transition to a revenue-generating medtech company.
- The breast cancer diagnostics market is currently valued in the low tens of billions of dollars and is projected to double or more over the next 8-10 years.
Oct 16, 2025, 12:30 PM
Odyssey Health, Inc. Secures Promissory Note and Issues Warrants
ODYY
Debt Issuance
New Projects/Investments
- Odyssey Health, Inc. entered into a Promissory Note Agreement with Peter D'Arruda, effective October 1, 2025, receiving $100,000.
- The Promissory Note is a one-year note with an 18% interest rate per annum, and the full outstanding amount plus accrued interest is due by September 30, 2026.
- In connection with the note, the company issued a warrant to Peter D'Arruda to purchase 100,000 shares of common stock at an exercise price of $0.10 per share.
Oct 8, 2025, 9:11 PM
Odyssey Health enters into debt and warrant agreement
ODYY
Debt Issuance
- Odyssey Health, Inc. entered into a Securities Purchase Agreement with Mast Hill Fund, L.P. on August 27, 2025.
- The agreement includes the issuance of a promissory note with a principal amount of $220,000.00, an interest rate of 10% per annum, and a 12-month maturity from the issue date. The note was purchased for $198,000.00.
- As additional consideration, Odyssey Health, Inc. issued warrants to purchase 1,000,000 shares of common stock at an exercise price of $0.10 per share, exercisable for five years from the issuance date.
Aug 29, 2025, 9:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more